Advertisement
Advertisement

VCEL

VCEL logo

Vericel Corporation

32.84
USD
Sponsored
-0.10
-0.30%
May 13, 16:00 UTC -4
Closed
exchange

Pre-Market

33.42

+0.58
+1.76%

Vericel Corporation Profile

About

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.

Info & Links

CEO

Dominick C. Colangelo

Headquarters

64 SIDNEY STREET
CAMBRIDGE, MA 02139, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.vcel.com

Auditor

PricewaterhouseCoopers LLP

Share holders

162

Employees

398

Vericel Corporation Statistics

Valuation Measures

Market Capitalization2

1.71B

Enterprise Value

1.61B

Enterprise Value/EBITDA(ttm)

71.02

Price to Earnings Ratio(ttm)

108.36

Price to Sales(ttm)

6.19

Price to Book(mrq)

4.79

Price to Cash(ytd)

60.47

Profitability

Gross Margin(ttm)

73.71%

Operating Margin(ttm)

5.98%

Profit Margin(ttm)

2.57%

Return on Equity(ttm)

5.17%

Return on Invested Capital(ttm)

4.14%

Return on Assets(ttm)

3.67%

Income Statement

Revenue(ttm)

276.26M

Revenue Per Share(ttm)

5.44

Gross Profit(ttm)

205.60M

EBITDA(ttm)3

22.62M

Net Income Available to Common(ttm)

16.52M

Diluted EPS(ttm)

0.31

Share Statistics

Beta (5Y Monthly)

1.20

52-Week Change

-24.75%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

50.76M

Dividend Yield

0.00%

Float4

47.06M

% Held by Insiders

7.60%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

137.50M

Total Cash Per Share(mrq)

2.71

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.03%

Quick Ratio(mrq)

4.68%

Book Value Per Share(mrq)

7.01

Cash Flow

Operating Cash Flow Per Share(ytd)

1.00

Free Cash Flow(ytd)

24.75M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement